ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX

ARK Investment Management LLC cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 4.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,510,404 shares of the company’s stock after selling 64,628 shares during the quarter. ARK Investment Management LLC owned 1.96% of Nurix Therapeutics worth $13,956,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Nurix Therapeutics by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after acquiring an additional 5,286 shares during the last quarter. Millennium Management LLC lifted its position in shares of Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock worth $10,388,000 after purchasing an additional 450,262 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after purchasing an additional 44,002 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Nurix Therapeutics by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock worth $1,895,000 after purchasing an additional 12,817 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Nurix Therapeutics by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 18,404 shares of the company’s stock valued at $210,000 after purchasing an additional 2,248 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the transaction, the insider directly owned 83,672 shares of the company’s stock, valued at $1,388,955.20. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. This represents a 7.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.40% of the company’s stock.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $16.26 on Thursday. The stock has a 50-day simple moving average of $17.45 and a 200 day simple moving average of $14.17. The stock has a market capitalization of $1.67 billion, a P/E ratio of -5.35 and a beta of 1.96. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%.The firm had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analysts Set New Price Targets

NRIX has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Wells Fargo & Company lowered their target price on Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Thursday, January 29th. Needham & Company LLC reiterated a “buy” rating and set a $26.00 target price on shares of Nurix Therapeutics in a report on Thursday, January 29th. HC Wainwright increased their price target on Nurix Therapeutics from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, Mizuho boosted their price target on Nurix Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.